Source: Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis ($NVS) CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly ($LLY) CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its…...
Cubist Pharmaceuticals: Ripe For Acquisition?
Source: Bidness ETC Threats from the increase in drug-resistant germs, and the subsequent rise in demand for more effective and high-impact antibiotics has spurred interest in companies such as Cubist Pharmaceuticals Inc (CBST). The Massachusetts-based drug developer has announced that it plans to introduce four new medicines to the market…...
After a 6-year delay, Medicines Co. bags FDA approval for once-troubled antibiotic
Source: FierceBiotech More than 5 years after The Medicines Company ($MDCO) bagged Targanta and its troubled antibiotic oritavancin for the bargain basement rate of $42 million plus potential bonus payments, the biotech has finally nailed down an elusive FDA approval of the product for skin infections caused by Gram-positive bacteria,…...